Chiudi

Aggiungi l'articolo in

Chiudi
Aggiunto

L’articolo è stato aggiunto alla lista dei desideri

Chiudi

Crea nuova lista

Malignant: How Bad Policy and Bad Evidence Harm People with Cancer - Vinayak K. Prasad - cover
Malignant: How Bad Policy and Bad Evidence Harm People with Cancer - Vinayak K. Prasad - cover
Dati e Statistiche
Wishlist Salvato in 0 liste dei desideri
Malignant: How Bad Policy and Bad Evidence Harm People with Cancer
Disponibile in 5 giorni lavorativi
34,44 €
-5% 36,25 €
34,44 € 36,25 € -5%
Disp. in 5 gg lavorativi
Chiudi
Altri venditori
Prezzo e spese di spedizione
ibs
34,44 € Spedizione gratuita
disponibile in 5 giorni lavorativi disponibile in 5 giorni lavorativi
Info
Nuovo
Altri venditori
Prezzo e spese di spedizione
ibs
34,44 € Spedizione gratuita
disponibile in 5 giorni lavorativi disponibile in 5 giorni lavorativi
Info
Nuovo
Altri venditori
Prezzo e spese di spedizione
Chiudi

Tutti i formati ed edizioni

Chiudi
Malignant: How Bad Policy and Bad Evidence Harm People with Cancer - Vinayak K. Prasad - cover
Chiudi

Promo attive (0)

Descrizione


How hype, money, and bias can mislead the public into thinking that many worthless or unproven treatments are effective. Each week, people read about new and exciting cancer drugs. Some of these drugs are truly transformative, offering major improvements in how long patients live or how they feel—but what is often missing from the popular narrative is that, far too often, these new drugs have marginal or minimal benefits. Some are even harmful. In Malignant, hematologist-oncologist Dr. Vinayak K. Prasad writes about the many sobering examples of how patients are too often failed by cancer policy and by how oncology is practiced. Throughout this work, Prasad illuminates deceptive practices which • promote novel cancer therapies long before credible data are available to support such treatment; and • exaggerate the potential benefits of new therapies, many of which cost thousands and in some cases hundreds of thousands of dollars. Prasad then critiques the financial conflicts of interest that pervade the oncology field, the pharmaceutical industry, and the US Food and Drug administration. This is a book about how the actions of human beings—our policies, our standards of evidence, and our drug regulation—incentivize the pursuit of marginal or unproven therapies at lofty and unsustainable prices. Prasad takes us through how cancer trials are conducted, how drugs come to market, and how pricing decisions are made, asking how we can ensure that more cancer drugs deliver both greater benefit and a lower price. Ultimately, Prasad says, • more cancer clinical trials should measure outcomes that actually matter to people with cancer; • patients on those trials should look more like actual global citizens; • we need drug regulators to raise, not perpetually lower, the bar for approval; and • we need unbiased patient advocates and experts. This well-written, opinionated, and engaging book explains what we can do differently to make serious and sustained progress against cancer—and how we can avoid repeating the policy and practice mistakes of the past.
Leggi di più Leggi di meno

Dettagli

2020
Hardback
304 p.
Testo in English
229 x 152 mm
544 gr.
9781421437637
Chiudi
Aggiunto

L'articolo è stato aggiunto al carrello

Chiudi

Aggiungi l'articolo in

Chiudi
Aggiunto

L’articolo è stato aggiunto alla lista dei desideri

Chiudi

Crea nuova lista

Chiudi

Chiudi

Siamo spiacenti si è verificato un errore imprevisto, la preghiamo di riprovare.

Chiudi

Verrai avvisato via email sulle novità di Nome Autore